Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
ContextImmune checkpoint blockades (ICBs) have been approved widely to treat various malignancies. Autoimmune diabetes mellitus, which can be caused by programmed cell death protein 1 (PD-1) inhibitors, is rare. Sintilimab, a monoclonal anti-PD-1 antibody, has been approved in China for the treatmen...
Main Authors: | Liang Wen, Xiuwen Zou, Yiwen Chen, Xueli Bai, Tingbo Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.02076/full |
Similar Items
-
Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
by: Qi Zhang, et al.
Published: (2020-10-01) -
Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas
by: Qi Zhang, et al.
Published: (2020-10-01) -
Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage
by: Qi Zhang, et al.
Published: (2021-06-01) -
A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma
by: Junli Wang, et al.
Published: (2021-09-01) -
Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges
by: Qi Zhang, et al.
Published: (2020-10-01)